- Home
- CMP vs XERS Comparison
CMP vs XERS Comparison
Compare CMP & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMP | XERS |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CMP | XERS |
|---|---|---|
| Price | $30.48 | $6.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $21.50 | $10.83 |
| AVG Volume (30 Days) | 708.5K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 0.73 | 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | $1.29 | $22.86 |
| P/E Ratio | ★ $40.68 | $638.48 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $16.40 | $4.30 |
| 52 Week High | $32.39 | $10.08 |
Technical Indicators
Market Signals| Indicator | CMP | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 65.31 | 49.57 |
| Support Level | $20.83 | $5.79 |
| Resistance Level | $32.39 | $6.41 |
| Average True Range (ATR) | 2.00 | 0.32 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 78.25 | 28.51 |
Price Performance
Historical ComparisonAbout CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.